3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
428
Neoplasms
296
Breast Neoplasms
296
Colorectal Neoplasms
241
Neoplasm Metastasis
196
Ovarian Neoplasms
171
Lung Neoplasms
149
Recurrence
148
Prostatic Neoplasms
146
Pancreatic Neoplasms
141
Multiple Myeloma
136
Stomach Neoplasms
129
Squamous Cell Carcinoma of Head and Neck
128
Melanoma
123
Leukemia, Myeloid, Acute
115
Endometrial Neoplasms
114
Advanced Solid Tumors
113
Advanced Solid Tumor
108
Carcinoma, Hepatocellular
102
Triple Negative Breast Neoplasms
101
Small Cell Lung Carcinoma
88
Uterine Cervical Neoplasms
86
Lymphoma, Non-Hodgkin
83
Carcinoma, Renal Cell
72
Lymphoma, Follicular
71
Lymphoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
65
Solid Tumor
64
Lymphoma, Large B-Cell, Diffuse
64
Hematologic Neoplasms
61
Interventions
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
enfortumab vedotin
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
Metastatic Urothelial Cancer
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA